Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Prior treatment

• Acute coronary syndrome, cardiac, carotid, or other major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty within six months prior to screening
• In T2DM, dipeptidyl peptidase-4 inhibitor use for one month prior to enrollment will be excluded due to possible interaction with LCZ696
• Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with non-steroidal anti-inflammatory drugs
• Treatment with greater than 5 mg of prednisone or equivalent dose of chronic systemic glucocorticoid therapy within the last year or recent (within 6 weeks of first study day) treatment with burst dosed glucocorticoid therapy
• Treatment with lithium salts
• Treatment with any investigational drug in the one month preceding the study

Other illness

• History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEi, ARBs, or neutral endopeptidase inhibitor (NEPi), as well as known or suspected contraindications to the study drugs
• History of angioedema
• History of decompensated HF within the last 3 months (exacerbation of chronic HF manifested by signs and symptoms that required intravenous therapy or hospitalization) or one month if hospitalized only once for initial diagnosis of HF
• History of heart transplant or on a transplant list or with left ventricular assistance device
• Coronary or carotid artery disease likely to require surgical or percutaneous intervention within six months of screening
• History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack with clinically significant residual deficits
• History of ventricular arrhythmia with syncopal episodes
• Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular (LV) dilatation
• Type 1 diabetes
• Poorly controlled type 2 diabetes mellitus (T2DM), defined as a HgbA1c \>9%
• History or presence of immunological or hematological disorders
• History of malignancy not felt to be cured, except non-melanoma skin cancer
• History of hypersensitivity reaction to contrast
• Clinically significant gastrointestinal impairment that could interfere with drug absorption
• History of pancreatitis or known pancreatic lesions
• History of alcohol or drug abuse
• Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study

Lab values

• Serum potassium \>5.2 mmol/L at screening or during the study
• Impaired renal function (eGFR of \<30mL/min/1.73 m2) as determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dL and age in years:
  • eGFR (mL/min/1.73 m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if female)
• Impaired hepatic function with evidence of advanced fibrosis or cirrhosis \[stable aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) trend if \>3.0 x upper limit of normal range as deemed of minimal clinical relevance by the investigators\]

Other

• Symptomatic hypotension and/or a systolic blood pressure (SBP)\<100 mmHg at screening or \<95 mmHg during the study
• Symptomatic bradycardia or second- or third-degree atrioventricular block without a pacemaker
• Presence of other hemodynamically significant obstructive lesions of the LV outflow tract, including aortic and subaortic stenosis
• Hematocrit \<35%
• Breast feeding and pregnancy
• Diagnosis of asthma requiring use of inhaled beta agonist more than once a week
• Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

• Black and white men and women
• Stable patients with a reduced ejection fraction (EF)
  • EF ≤55%, and
  • history of symptoms of New York Heart Association (NYHA) class I, II, or III heart failure (HF)
  • stable clinical symptoms including no hospitalizations for the last three months, or one month if hospitalized only once for initial diagnosis of HF
  • who are not already taking LCZ696
• treatment with a stable dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) and with a beta blocker (unless contraindicated or not tolerated) for at least four weeks
• for patients with NYHA Class II or III HF and EF ≤35%, treatment with a stable dose of an mineralocorticoid receptor (MR) antagonist for at least four weeks, unless not possible due to renal function or adverse reaction
• For female subjects, the following conditions must be met:
  • postmenopausal status for at least one year
  • status post-surgical sterilization
  • or if childbearing potential, utilization of barrier methods of birth control or an oral contraceptive and willingness to undergo urine β-HCG testing on every study day
• Age 18 years of age or older